117 related articles for article (PubMed ID: 2856451)
21. Tamoxifen withdrawal response. Report of a case.
Belani CP; Pearl P; Whitley NO; Aisner J
Arch Intern Med; 1989 Feb; 149(2):449-50. PubMed ID: 2537066
[TBL] [Abstract][Full Text] [Related]
22. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
[TBL] [Abstract][Full Text] [Related]
23. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
[TBL] [Abstract][Full Text] [Related]
24. Clinical experiences with tamoxifen for estrogen receptor blocking therapy in metastatic breast cancer.
Henningsen B
Prog Clin Biol Res; 1977; 12():479-82. PubMed ID: 918118
[No Abstract] [Full Text] [Related]
25. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
[TBL] [Abstract][Full Text] [Related]
26. [ASCO/CAP guidelines and recommendations on hormonal receptor testing in breast cancer].
Wang T; Jiang ZF
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):721-2. PubMed ID: 21215158
[No Abstract] [Full Text] [Related]
27. [Intracystic papillary carcinoma of the breast: report of three cases].
El mazghi A; Bouhafa T; Loukili K; El kacemi H; Lalya I; Kebdani T; Hassouni K
Pan Afr Med J; 2014; 18():207. PubMed ID: 25419333
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen for patients with estrogen receptor-negative breast cancer.
Swain SM
J Clin Oncol; 2001 Sep; 19(18 Suppl):93S-97S. PubMed ID: 11560981
[No Abstract] [Full Text] [Related]
29. Guidelines on endocrine therapy of breast cancer EUSOMA.
Blamey RW;
Eur J Cancer; 2002 Mar; 38(5):615-34. PubMed ID: 11916542
[No Abstract] [Full Text] [Related]
30. [A case of male breast cancer with special reference to the hormonal environment during chemoendocrine therapy].
Saito K; Hotta T; Kobayashi S; Miura I; Sakuma S; Shimozato T; Torii T; Iwase H; Satake A; Nishida T
Gan No Rinsho; 1985 Oct; 31(13):1727-30. PubMed ID: 3001383
[TBL] [Abstract][Full Text] [Related]
31. Use of tamoxifen in advanced male breast cancer.
Patterson JS; Battersby LA; Bach BK
Cancer Treat Rep; 1980; 64(6-7):801-4. PubMed ID: 7427964
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.
Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M
J Am Coll Surg; 2005 Nov; 201(5):688-94. PubMed ID: 16256910
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
34. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
35. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
36. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
38. [Hormone therapy of breast carcinoma in men].
Doberauer C; Niederle N
Dtsch Med Wochenschr; 1990 Nov; 115(46):1762-8. PubMed ID: 2171893
[No Abstract] [Full Text] [Related]
39. The estrogen receptor: a model for molecular medicine.
Jensen EV; Jordan VC
Clin Cancer Res; 2003 Jun; 9(6):1980-9. PubMed ID: 12796359
[TBL] [Abstract][Full Text] [Related]
40. 1998-1999 patterns of care study process survey of national practice patterns using breast-conserving surgery and radiotherapy in the management of stage I-II breast cancer.
Pierce LJ; Moughan J; White J; Winchester DP; Owen J; Wilson JF
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):183-92. PubMed ID: 15850920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
